Keith Mikule

Company: Insilico Medicine

Job title: Vice President, Business Development

Seminars:

AI-Powered Target Identification in DNA Damage Repair: Hypotheses for Validation 1:15 pm

Reviewing how AI identifies and analyzes synthetic lethal DNA damage repair (DDR) targets, offering new therapeutic opportunities Uncovering the rationale behind selecting WRN and USP1, supported by AI-driven insights into their potential roles in synthetic lethality and cancer treatment Progress and speed in advancing chemistry with AI, from target discovery to drug development, optimizing efficiency…Read more

day: Day Two